SARS-CoV-2 vaccines, administered to billions of people worldwide, mitigate the effects of the COVID-19 pandemic, however little is known about the molecular basis of antibody cross-protection to emerging variants, such as Omicron BA.1, its sublineage BA.2, and other coronaviruses. To answer this question, 276 neutralizing monoclonal antibodies (nAbs), previously isolated from seronegative and seropositive donors vaccinated with BNT162b2 mRNA vaccine, were tested for neutralization against the Omicron BA.1 and BA.2 variants, and SARS-CoV-1 virus. Only 14.2, 19.9 and 4.0% of tested antibodies neutralize BA.1, BA.2, and SARS-CoV-1 respectively. These nAbs recognize mainly the SARS-CoV-2 receptor binding domain (RBD) and target Class 3 and Class 4 epitope regions on the SARS-CoV-2 spike protein. Interestingly, around 50% of BA.2 nAbs did not neutralize BA.1 and among these, several targeted the NTD. Cross-protective antibodies derive from a variety of germlines, the most frequents of which were the IGHV1-58;IGHJ3-1, IGHV2-5;IGHJ4-1 and IGHV1-69;IGHV4-1. Only 15.6, 20.3 and 7.8% of predominant gene-derived nAbs elicited against the original Wuhan virus cross-neutralize Omicron BA.1, BA.2 and SARS-CoV-1 respectively. Our data provide evidence, at molecular level, of the presence of cross-neutralizing antibodies induced by vaccination and map conserved epitopes on the S protein that can inform vaccine design.
Since its first appearance in December 2019, more than 495 million cases of SARS-CoV-2 infections were reported worldwide, with over 6.1 million deaths. Effective vaccines against the virus that first appeared in Wuhan, China, have been developed with unprecedented speed. However, their ability to contain the global pandemic has been compromised by the inability to timely deliver vaccines to low-income countries and by the appearance of several antigenic variants which escaped the natural and vaccine-induced immunity1,2,3. The main variants that emerged so far, and are listed as variants of concern (VoCs), are named B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529.1 (Omicron; BA.1)4,5. The latter one showed to be the most efficient in spreading into partially immune populations and in a few months from its appearance has conquered most regions of the world6,7. Shortly after the appearance of the Omicron variant BA.1, the sublineage BA.2 (B.1.1.529.2) was identified, and it is now replacing the initial BA.1 variant worldwide8,9. Previous reports have shown that the unprecedented number of mutations carried on the Omicron BA.1 and BA.2 S protein drastically reduce the neutralizing efficacy of sera from infected and vaccinated people and that this VoC can escape more than 85% of nAbs described in literature, including several antibodies approved for clinical use by regulatory agencies10,11,12,13,14,15,16,17,18. Despite these observations, recent reports have shown different profiles of immune evasion between omicron BA.1 and BA.219,20,21. While serum activity and neutralization efficacy of selected monoclonal antibodies against Omicron BA.1 and BA.2 have been reported, the functional and genetic anatomy of nAbs elicited in naïve (seronegative) and convalescent (seropositive) people immunized with two doses of the BNT162b2 mRNA vaccine remains to be explored. Taking advantage of our previous work22, we tested 276 human monoclonal antibodies able to neutralize the original SARS-CoV-2 virus isolated in Wuhan, for their ability to neutralize the Omicron BA.1 and BA.2 variants, and the distantly related SARS-CoV-1 virus. Our work unravels the genetic signature of cross-protective antibodies and mapped conserved sites of pathogen vulnerability on the S protein that can be used to design the next generation of sarbecovirus vaccines.
Distribution of BA.2 and BA.2 mutations on immunodominant sites
The SARS-CoV-2 B.1.1.529.1 (BA.1) and B.1.1.529.2 (BA.2) Omicron variants harbor 37 and 31 mutated residues in the spike (S) glycoprotein respectively (Supplementary Fig. 1a). The receptor binding domain (RBD) and N terminal domain (NTD) immunodominant sites are both highly mutated14,19. The NTDs of BA.1 and BA.2 carry 11 and 7 mutations respectively. BA.1 shows to be more remodeled compared to BA.2, presenting three substitutions (27%), A67V, T95I, and G142D, 5 deleted residues (46%), Δ69–70 and Δ143–145, and three inserted residues (27%), ins214EPE. On the other hand, BA.2 presents a NTD more similar to the original Wuhan virus carrying only four substitutions (57%), T19I, A27S, G142D, and V213G, and three deleted residues (43%), Δ24–26. The RBDs of BA.1 and BA.2 show a lower degree of plasticity compared to NTD, as only substituted residues are present in this domain. Within the RBD, which contains 15 and 16 mutations in total, the receptor binding motif (RBM), spanning from residues S438 to Y50823, is the most mutated region. In fact, BA.1 RBM contains 10/15 (67%) mutated residues, while BA.2 carries 8/16 (50%) mutations. The eight mutated residues in the RBM of BA.2 are all shared with BA.1. Mutated residues in the RBM overlap with the epitopes of Class 1 and Class 2 neutralizing antibodies (nAbs), like J0824,25, that target epitopes spanning from the left shoulder, through the neck and upper part of the right shoulder of the S protein (Supplementary Fig. 1b–d)26,27. Class 3 and 4 clusters of antibodies target the lower portion of the RBD, and their epitopes are located on the right and left flanks of this domain. Class 3 nAbs, like S30928, target the right flank of the RBD where only 2/15 (13%) and 2/16 (12%) of all BA.1 and BA.2 mutations are found respectively (Supplementary Fig. 1d). Class 4 mAbs, like CR302229, are directed towards the left flank of the RBD which shows 3/15 (20%) and 6/16 (37%) mutations for BA.1 and BA.2 respectively (Supplementary Fig. 1b).
Omicron effects on vaccine-induced nAbs
To understand the impact of SARS-CoV-2 Omicron on the antibody response, we evaluated the neutralization activity of 276 nAbs previously isolated from seronegative (n = 52) and seropositive (n = 224) donors immunized with the BNT162b2 mRNA vaccine (Fig. 1)22. Data obtained from the neutralization analyses against Omicron BA.1 and BA.2 were compared with the neutralization data against the original Wuhan virus analyzed in our previous work22. While BA.1 cross-neutralizing nAbs were identified in all seropositives, these antibodies were found only in one out of five seronegatives (20%). Conversely, BA.2 cross-neutralizing nAbs were identified in all seropositives and in three out of five seronegatives (60%) (Supplementary Table 1). Only 1/52 (1.9%) and 4/52 (7.7%) nAbs from seronegatives neutralized Omicron BA.1 and BA.2 respectively, with a medium-low neutralization potency (Fig. 1a, c, d, f). As for seropositive vaccinees, 38/224 (17.0%) BA.1 and 51/224 (22.8%) BA.2 nAbs were identified (Fig. 1b, c, e, f). BA.1 nAbs showed a 3.16-fold decreased neutralization potency compared to the Wuhan virus, while BA.2 nAbs showed only a 1.76-fold decrease (Fig. 1b, c, e, f). Overall, 39 and 55 nAbs against BA.1 and BA.2 were identified respectively and none of these antibodies showed an extreme neutralization potency (IC100 below 10 ng ml−1). To identify immunodominant sites of neutralization against BA.1 and BA.2, a flow cytometry-based competition assay was performed. In our previous study, we found that 215/276 (77.9%; 37 from seronegatives and 178 from seropositives) nAbs bound to the S protein RBD and the majority of these antibodies were competing with J08, which epitope spans between Class 1 and Class 2 regions, and S309, which target the Class 3 region22. In this work, all 215 RBD targeting-nAbs were additionally tested by competition assay against Class 4 targeting mAb CR3022. While Class 1/2, Class 3 and Not-competing nAbs were found in both seronegatives and seropositives, Class 4 competing nAbs were found exclusively in seropositives (Supplementary Fig. 2a; Supplementary Table 2). In both groups, Class 1/2 competing nAbs was the most abundant (70.3% in seronegatives and 64.0% in seropositives), followed by Not-competing (10.8%) and Class 3-competing nAbs (27.0%) for seronegatives and seropositives respectively. When tested for their neutralization activity against the BA.1 and BA.2 omicron variants, we observed that RBD-targeting Class 3 directed nAbs are the most abundant and potent class of nAbs against both BA.1 (29%) and BA.2 (52%) (Fig. 2b–d). In terms of overall neutralization potency, GM-IC100, BA.1 nAbs showed a higher loss compared to BA.2 nAbs (Fig. 2d). Following, we evaluated the binding distribution of the 39 BA.1 and 55 BA.2 neutralizing antibodies and investigated the class of nAbs able to cross-neutralize both Omicron variants. Of the 39 BA.1 nAbs, the majority recognized the Class 1/2 region (n = 20; 51.3%), followed by Class 3 (n = 15; 38.5%), while nAbs targeting Class 4 region (n = 1; 2.6%), Not-competing (n = 2; 5.1%) and targeting the NTD (n = 1; 2.6%) were the least represented (Fig. 2e–g). As for the 55 BA.2 nAbs, the majority recognized the RBD Class 3 region (n = 27; 49.1%), followed by Class 1/2 (n = 18; 32.7%), NTD-targeting nAbs (n = 9; 16.4%), and Class 4 nAbs (1.8%) (Fig. 2e–g). Cross-Omicron variants nAbs were also characterized. While up to 74% (n = 29/39) of BA.1 nAbs were able to neutralize BA.2, only 53% (n = 29/55) of BA.2 nAbs showed cross-functional activity against BA.1. The majority of cross-Omicron nAbs were represented by Class 1/2 targeting nAbs (n = 15; 51.7%), followed by Class 3 (n = 13; 44.8%) and Class 4 (n = 1; 3.4%) targeting nAbs. None of the NTD-targeting nAbs were found to be cross-functional (Fig. 2e–g).
Antibody cross-protection to SARS-CoV-1
We investigated the ability of the BNT162b2 COVID-19 mRNA vaccine-elicited nAbs to neutralize the distantly related SARS-CoV-1 (SARS1) virus, using a lentiviral vector derived pseudoparticles, to identify immunodominant sites of cross-protection to different coronaviruses30. All 276 previously identified nAbs were tested for their ability to bind the SARS1 S protein (Supplementary Fig. 2b, c). Four out of five seropositives (80%) and one out of five seronegatives (20%) showed nAbs able to bind the SARS1 S protein (Supplementary Fig. 3a; Supplementary Table 1). Of the 52 nAbs isolated from seronegatives 3 (5.8%) recognized SARS1 S protein, while 16 out of 224 nAbs (7.1%) from seropositives were able to bind this antigen (Supplementary Fig. 3a; Supplementary Table 1). When nAbs were tested for their neutralization activity against SARS1, only 1 (1.9%) and 10 (4.5%) nAbs were found from seronegatives and seropositives respectively (Supplementary Fig. 3b; Supplementary Table 1). All SARS1 cross-neutralizing nAbs recognized the SARS-CoV-2 S protein RBD. Class 4 targeting nAbs able to cross-neutralize SARS1 were overall the most frequent, followed by Class 3 binding nAbs (Supplementary Fig. 3c; Supplementary Table 1). While Class 4 was the most frequent, Class 3 targeting nAbs showed the highest neutralization potency (Supplementary Fig. 3c, d; Supplementary Table 1). None of the 140 Class 1/2 regions targeting nAbs were able to cross-neutralize SARS1. Among the 11 SARS1 cross-neutralizing nAbs, the majority recognized the Class 3 region (n = 6; 54.5%), followed by Class 4 (n = 4; 36.4%) and Not-competing (n = 1; 9.1%) nAbs (Supplementary Fig. 3c, d).
Antibody repertoire to Omicron and SARS-CoV-1
To investigate the genetic basis of antibody cross-protection against BA.1, BA.2, and SARS1, we interrogated the functional antibody repertoire. In our previous work, we identified five predominant germlines shared among seronegatives and seropositives (IGHV1-2;IGHJ6-1, IGHV1–69;IGHJ4-1, IGHV3–30;IGHJ6-1, IGHV3–53;IGHJ6-1 and IGHV3–66;IGHJ4-1), and one rearrangement (IGHV2–5;IGHJ4-1), that encoded for potently neutralizing antibodies able to protect against all VoC from alpha (B.1.1.7) to delta (B.1.617.2), found exclusively in seropositives (Fig. 3a, top panel)22. Cross-protective nAbs against BA.1, BA.2, and SARS1 use a variety of genetic rearrangements (Fig. 3a, top, middle, and bottom heatmaps). The most frequent among BA.1 nAbs was the non-predominant gene rearrangement IGHV1–58;IGHJ3-1 (64.0%; 7/11) found in both seronegatives and seropositives, while predominant gene-derived nAbs only rarely were able to neutralize BA.1 (10/64; 15.6%) (Fig. 3a, top panel, and b-h). The most abundant germline among BA.2 nAbs is the predominant IGHV2–5;IGHJ4-1 gene family (6/7; 86%), while the remaining 57 predominant gene-derived nAbs poorly neutralized this variant (7/57; 12.3%) as observed for BA.1 (Fig. 3). Interestingly, we found that IGHV1–24;IGHJ6-1 gene-derived nAbs, known to encode for NTD-targeting antibodies31, are abundantly used to protect from BA.2 but not from BA.1 or SARS1. As for SARS1 cross-neutralizing antibodies, only 7.8% (5/64) of the previously identified predominant germlines showed protection (Fig. 3i). Despite this observation, the most abundant germline used by these nAbs was the predominant IGHV1–69;IGHJ4-1 (4/; 22%) which was found in both seronegatives and seropositives and showed a medium-high 50% neutralization dose (ND50) (Fig. 3a, top panel; Fig. 3i). None of the predominant gene-derived antibodies able to neutralize BA.1 and BA.2 cross-neutralized SARS1. We further analyzed the IGHV1–58;IGHJ3-1, IGHV2–5;IGHJ4-1 and IGHV1–69;IGHJ4-1 germlines which showed to be predominant in the functional response against BA.1, BA.2 and SARS1 and observed key differences among these rearrangements. All IGHV1–58;IGHJ3-1 nAbs bound the RBD and targeted Class 1/2 region (Supplementary Fig. 4a, d), and had heavy chain complementary determining region 3 (CDRH3) length of 16 amino acid (aa) with a median V gene mutation level of 3% (Fig. 3j). All IGHV2–5;IGHJ4-1 bound the RBD and targeted the Class 3 region on the RBD, carrying mainly a CDRH3 length of 10 aa and a median V gene mutation level of 3% (Fig. 3k; Supplementary Fig. 4b, d). IGHV1–58;IGHJ3-1 and IGHV2–5;IGHJ4-1 nAbs shows similar genetic characteristics independently from their ability to neutralize BA.1 and BA.2 respectively compared to the original Wuhan virus. IGHV1–69;IGHJ4-1 derived nAbs showed to be able to recognize both NTD and RBD, and to target Class 1/2 and Class 3 regions on this latter domain (Supplementary Fig. 4c, d). Conversely, IGHV1–69;IGHJ4-1 SARS1 nAbs, showed to bind only to the RBD and to target exclusively the Class 3 epitope region (Supplementary Fig. 4c, d). IGHV1–69;IGHJ4-1 nAbs showed to use a heterogenous CDRH3 length with SARS1 nAbs spanning from 11 to 12 amino acids and V gene mutation levels averaging 3.4% (Fig. 3l).
In this work, we deeply characterized an extensive panel of BNT162b2 mRNA vaccine elicited-neutralizing human monoclonal antibodies against the heavily mutated Omicron variant BA.1, its sublineage BA.2, and the distantly related SARS-CoV-1. We found that only 14.2, 19.9. and 4.0% of our antibody panel was able to neutralize the Omicron BA.1, BA.2, and the SARS-CoV-1 virus respectively. Remarkably, from the group of seronegative people vaccinated with two doses of the BNT162b2 mRNA vaccine, we observed that only 5 of the 52 nAbs were able to neutralize BA.1 and BA.2, while none of their antibodies retained functionality against SARS-CoV-1. Cross-neutralizing antibodies were mainly isolated from vaccinees with previous infection, highlighting once again the broad cross-protection conferred by hybrid immunity22,32. Despite these results, we observed that antibody germlines mainly involved in BA.1 and SARS-CoV-1 cross-protection (IGHV1–58;IGHJ3-1 and IGHV1–69;IGHJ4-1) were used in both seronegative and seropositive vaccinees and differed from those initially identified against the original Wuhan virus and pre-omicron variants33,34. Interestingly, cross-protection to BA.2 was mainly driven by the Class 3 targeting germline IGHV2–5;IGHJ4-1, which was found to poorly neutralize BA.1. This scenario could partially be explained by the lack of the G446S mutation on the BA.2 spike protein, as mutations on this residue were previously shown to evade Class 3 targeting antibodies35. In addition to RBD-targeting antibodies, nAbs targeting the NTD “supersite” also showed to participate in the cross-protection to BA.2, as this sublineage shows a lower degree of mutations in this domain compared to BA.1. The re-acquired functionality of IGHV2–5;IGHJ4-1 Class 3 and NTD-targeting nAbs could partially explain, at the molecular level, the reason behind the higher nAbs neutralization potency to BA.2 observed in this study as well as the higher serum neutralization activity observed against BA.2 compared to BA.1 in vaccinated subjects21. Overall, this scenario suggests that a third booster dose in naïve people could enhance germline maturation and induce a more broad and persistent antibody response36. Firstly, a third booster dose could drive affinity maturation of poorly cross-reactive but predominant RBD-targeting B cell germlines elicited following SARS-CoV-2 Wuhan infection or vaccination, which were shown to persist for up to 6 months in the draining lymph nodes of vaccinated individuals37. Secondly, a third booster dose will also expand the population of NTD-targeting B cells, which were previously shown to be a prime target of COVID-19 mRNA vaccination12,38, and could therefore play a pivotal role in the cross-protection against the fast-spreading BA.2 omicron variant. In addition, these data suggest that primary immunization with two doses of vaccine in naïve people is not sufficient to elicit a meaningful proportion of cross-neutralizing antibodies and that this requires a secondary immune response that can be obtained by vaccinating previously infected people or by providing a third booster dose39. Further studies will be necessary to understand whether a booster dose in naïve people can elicit a hybrid immunity-like antibody response and to define the molecular basis of cross-protection in this population. In addition to previous observations on the activity of different classes of antibodies against SARS-CoV-2 and related sarbecoviruses40,41,42,43,44, we herein comprehensively defined for the first time the anatomy of BA.1, BA.2, and SARS-CoV-1 neutralizing antibodies, highlighting epitope regions and predominant germlines responsible for cross-protection to these viruses. Our data can support the design of next-generation COVID-19 vaccines broadly protective against current and future coronavirus threats.
Enrollment of COVID-19 vaccinees and human sample collection
Human neutralizing antibodies tested in this work were isolated from COVID-19 vaccinated donors, of both sexes (six males and four females), who gave their written consent, thanks to a collaboration with the Azienda Ospedaliera Universitaria Senese, Siena (IT). The study was approved by the Comitato Etico di Area Vasta Sud Est (CEAVSE) ethics committees (Parere 17065 in Siena) and conducted according to good clinical practice in accordance with the declaration of Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997). This study was unblinded and not randomized. No statistical methods were used to predetermine sample size.
Transcriptionally active PCR expression of neutralizing antibodies
The transcriptionally active PCR (TAP) expression of neutralizing antibodies (nAbs) was performed as previously described22,25. Antibodies heavy and light chain vectors were initially digested using restriction enzymes AgeI, SalI, and Xho. PCR II products were ligated using the Gibson Assembly NEB into 25 ng of respective human Igγ1, Igκ, and Igλ expression vectors45,46. TAP reaction was performed using 5 μl of Q5 polymerase (NEB), 5 μl of GC Enhancer (NEB), 5 μl of 5X buffer, 10 mM of dNTPs, 0.125 μl of forward/reverse primers (forward: TTAGGCACCCCAGGCTTTAC; reverse: AGATGGTTCTTTCCGCCTCA) and 3 μl of ligation product, using the following cycles: 98 °C for 2 min, 35 cycles 98 °C for 10 s, 61 °C for 20 s, 72 °C for 1 min and 72 °C for 5 min. TAP products were purified, quantified using the Qubit Fluorometric Quantitation assay (Invitrogen), and used for transient transfection in Expi293F cell line (Thermo Fisher, Cat# A14527) following the manufacturer’s instructions.
SARS-CoV-2 BA.1 and BA.2 authentic viruses neutralization assay
All SARS-CoV-2 authentic virus neutralization assays were performed in the biosafety level 3 (BSL3) laboratories at Toscana Life Sciences in Siena (Italy) and Vismederi Srl, Siena (Italy). BSL3 laboratories are approved by a Certified Biosafety Professional and are inspected every year by local authorities. To evaluate the neutralization activity of identified nAbs against SARS-CoV-2 and BA.1 and BA.2 Omciron VoCs a cytopathic effect-based microneutralization assay (CPE-MN) was performed22,25. Briefly, nAbs were co-incubated with a SARS-CoV-2 viral solution containing 100 median Tissue Culture Infectious Dose (100 TCID50) of virus for 1 h at 37 °C, 5% CO2. The mixture was then added to the wells of a 96-well plate containing a sub-confluent Vero E6 cell monolayer (ATCC, Cat# CRL-1586). Plates were incubated for 3–4 days at 37 °C in a humidified environment with 5% CO2, then examined for CPE by means of an inverted optical microscope by two independent operators. All nAbs were tested at a starting dilution of 1:10, diluted step 1:2, and the IC100 was evaluated based on their initial concentration. Technical duplicates for each experiment were performed. In each plate, positive and negative control were used as previously described22,25.
SARS-CoV-2 virus variants CPE-MN neutralization assay
The SARS-CoV-2 Omicron BA.1 (B.1.1.529.1) and BA.2 (B.1.1.529.2) viruses used to perform the CPE-MN neutralization assay was supplied and sequenced by the NRC UZ/KU Leuven (Leuven, Belgium). Sequences were deposited on GISAID with the following ID: EPI_ISL_6794907 (BA.1) and EPI_ISL_10654979 (BA.2).
SARS-CoV-2 S protein competition assay
A competitive flow cytometry-based assay was performed to characterize nAbs binding profiles to SARS-CoV-2 S-protein as previously described22. Briefly, magnetic beads (Dynabeads His-Tag, Invitrogen) were covered with His-tagged S-proteins, following manufacturers’ instructions. Then, 40 mg/mL of beads-bound-S-protein were incubated with unlabeled nAbs for 40 min at RT. Following incubation, samples were washed with PBS and incubated with fluorescently labeled Class 1/2 (J08-A647), Class 3 (S309-A488), or Class 4 (CR3022-A647) S-protein nAbs binders. Antibodies labeling was performed using Alexa Fluor NHS Ester kit (Thermo Scientific). Following 40 min of incubation at RT, the beads-antibodies mix was washed with PBS, resuspended in 150 μl of PBS-BSA 1%, and acquired using BD LSR II flow cytometer (Becton Dickinson). Results were analyzed using FlowJo™ Software (version 10). Beads with or without S-protein incubated with labeled antibodies were used as positive and negative controls respectively.
SARS-CoV-1 S protein binding assay
Expi293F cells (Thermo Fisher, Cat# A14527) were transiently transfected with SARS-CoV-1 S-protein expression vectors (pcDNA3.3_CoV1_D28) using Expifectamine Enhancer according to the manufacturer’s protocol (Thermo Fisher). Two days later, to exclude dead cells from analysis, Expi293F were harvested, dispensed into a 96-well plate (3 × 105 cell/well), and stained for 30 min at room temperature (RT) with Live/Dead Fixable Aqua reagent (Invitrogen; Thermo Scientific) diluted 1:500. Following Live/Dead staining, cells were washed with PBS and incubated with nAbs candidates for 40 min at RT. Next, to identify the SARS-CoV-1 S protein mAbs binders, cells were washed and stained with the Alexa Fluor 488-labeled secondary antibody Goat anti-Human IgG (H + L) secondary antibody (Invitrogen) diluted 1:500. After 40 min of incubation, labeled cells were washed, resuspended in 150 μl of PBS, and analyzed using the BD LSR II flow cytometer (Becton Dickinson). Cells incubated with the SARS-CoV-1 nAb binder (S309) or incubated only with the secondary antibody were used as positive and negative controls respectively. Data were collected with the BD FACSDiva Software v9.0 (BD Biosciences) and analyzed with FlowJo™ Software (version 10).
HEK293TN-hACE2 cell line generation
HEK293TN-hACE2 cell line was generated by lentiviral transduction of HEK293TN (System Bioscience, Cat# LV900A-1) cells as described in Notarbartolo et al.47. Lentiviral vectors were produced following a standard procedure based on calcium phosphate co-transfection with 3rd generation helper and transfer plasmids. The transfer vector pLENTI_hACE2_HygR was obtained by cloning of hACE2 from pcDNA3.1-hACE2 (a gift from Fang Li, Addgene #145033) into pLenti-CMV-GFP-Hygro (a gift from Eric Campeau & Paul Kaufman, Addgene #17446). pLENTI_hACE2_HygR is now made available through Addgene (Addgene #155296). HEK293TN-hACE2 cells were maintained in DMEM, supplemented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin, and 250 μg/ml Hygromycin (GIBCO).
Production of SARS-CoV-1 pseudoparticles
SARS-CoV1 lentiviral pseudotype particles were generated as described in Conforti et al. for SARS-CoV-230. SARS-CoV1 SPIKE plasmid pcDNA3.3_CoV1_D28 is a gift from a gift from David Nemazee (Addgene plasmid # 170447).
SARS-CoV-1 neutralization assay
For neutralization assay, HEK293TN-hACE2 cells (System Bioscience, Cat# LV900A-1) were plated in white 96-well plates in a complete DMEM medium. 24 h later, cells were infected with 0.1 MOI of SARS-CoV-1 pseudoparticles that were previously incubated with serial dilution of purified or not purified (cell supernatant) mAb. In particular, a 7-point dose-response curve (plus PBS as untreated control), was obtained by diluting mAb or supernatant respectively five-fold and three-fold. Thereafter, nAbs of each dose-response curve point was added to the medium containing SARS-CoV-1 pseudoparticles adjusted to contain 0.1 MOI. After incubation for 1 h at 37 °C, 50 µl of mAb/SARS-CoV-1 pseudoparticles mixture was added to each well and plates were incubated for 24 h at 37 °C. Each point was assayed in technical triplicates. After 24 h of incubation cell infection was measured by luciferase assay using Bright-Glo™ Luciferase System (Promega) and Infinite F200 plate reader (Tecan) was used to read luminescence. Obtained relative light units (RLUs) were normalized to controls and dose-response curves were generated by nonlinear regression curve fitting with GraphPad Prism Version 8.0.2 (GraphPad Software, Inc., San Diego, CA) to calculate Neutralization Dose 50 (ND50).
Functional repertoire analyses
nAbs VH and VL sequence reads were manually curated and retrieved using CLC sequence viewer (Qiagen). Aberrant sequences were removed from the data set. Analyzed reads were saved in FASTA format and the repertoire analyses were performed using Cloanalyst (http://www.bu.edu/computationalimmunology/research/software/)48,49.
Statistical analysis was assessed with GraphPad Prism Version 8.0.2 (GraphPad Software, Inc., San Diego, CA). Nonparametric Mann–Whitney t test was used to evaluate statistical significance between the two groups analyzed in this study. Statistical significance was shown as * for values ≤0.05, ** for values ≤0.01, *** for values ≤0.001, and **** for values ≤0.0001.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Source data are provided with this paper. All data supporting the findings in this study are available within the article or can be obtained from the corresponding author upon request. Source data are provided with this paper.
Asundi, A., O’Leary, C. & Bhadelia, N. Global COVID-19 vaccine inequity: the scope, the impact, and the challenges. Cell Host Microbe 29, 1036–1039 (2021).
Kavanagh, M. M., Gostin, L. O. & Sunder, M. Sharing technology and vaccine doses to address global vaccine inequity and end the COVID-19 pandemic. JAMA 326, 219–220 (2021).
Andreano, E. & Rappuoli, R. SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nat. Med. 27, 759–761 (2021).
Burki, T. The origin of SARS-CoV-2 variants of concern. Lancet Infect. Dis. 22, 174–175 (2022).
Callaway, E. Beyond Omicron: what’s next for COVID’s viral evolution. Nature 600, 204–207 (2021).
Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398, 2126–2128 (2021).
Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022).
Mykytyn, A. Z. et al. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants. Preprint at bioRxiv https://doi.org/10.1101/2022.02.23.481644 (2022).
Chen, L.-L., Chu, A. W.-H., Zhang, R. R.-Q., Hung, I. F.-N. & To, K. K.-W. Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2. Lancet Microbe 3, E404 (2022).
Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).
Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
Carreño, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).
Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 189, 447–456.e11 (2022).
McCallum, M. et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 0, eabn8652 (2022).
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490–495 (2022).
Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477–480 (2022).
Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484.e15 (2022).
Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N. Engl. J. Med. 386, 1579–1580 (2022).
Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. https://doi.org/10.1038/s41591-022-01792-5 (2022).
Bowen, J. E. et al. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. Preprint at bioRxiv https://doi.org/10.1101/2022.03.15.484542 (2022).
Andreano, E. et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature 600, 530–535 (2021).
Yi, C. et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell. Mol. Immunol. 17, 621–630 (2020).
Torres, J. L. et al. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proc. Natl. Acad. Sci. https://doi.org/10.1073/pnas.2120976119 (2022).
Andreano, E. et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell 184, 1821–1835.e1816 (2021).
Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687 (2020).
Dejnirattisai, W. et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell 184, 2183–2200.e2122 (2021).
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020).
Conforti, A. et al. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol. Ther.: J. Am. Soc. Gene Ther. 30, 311–326 (2022).
Voss William, N. et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science 372, 1108–1112 (2021).
Crotty, S. Hybrid immunity. Science 372, 1392–1393 (2021).
Vanshylla, K. et al. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell host microbe 30, 69–82.e10 (2022).
Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119–1123 (2020).
Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).
Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021).
Laidlaw, B. J. & Ellebedy, A. H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7–18 (2022).
Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936–3948.e3910 (2021).
Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088–1091 (2022).
Hastie Kathryn, M. et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science 374, 472–478 (2021).
Tan, C.-W. et al. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N. Engl. J. Med. 385, 1401–1406 (2021).
Martinez David, R. et al. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Sci. Transl. Med. 14, eabj7125 (2022).
Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103–108 (2021).
Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021).
Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112–124 (2008).
Wardemann, H. & Busse, C. E. Expression cloning of antibodies from single human B cells. Methods Mol. Biol. 1956, 105–125 (2019).
Notarbartolo, S. et al. Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. Sci. Immunol. 6, eabg5021 (2021).
Kepler, T. B. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. F1000Res 2, 103–103 (2013).
Kepler, T. B. et al. Reconstructing a B-cell clonal lineage. II. Mutation, selection, and affinity maturation. Front. Immunol. 5, 170 (2014).
This work was funded by the European Research Council (ERC) advanced grant agreement number 787552 (vAMRes). This work was supported by a fundraising activity promoted by Unicoop Firenze, Coop Alleanza 3.0, Unicoop Tirreno, Coop Centro Italia, Coop Reno e Coop Amiatina. This publication was supported by the COVID-2020-12371817 project, which received funding from the Italian Ministry of Health. Piet Maes acknowledges support from the Research Foundation Flanders (COVID19 research grant G0H4420N) and Internal Funds KU Leuven (grant 3M170314). We would also like to acknowledge Dr. Jason McLellan, for kindly providing the SARS-CoV-2 and SARS1 S protein trimers, RBD, and NTD.
R.R. is an employee of the GSK group of companies. E.A., I.P., N.M., P.P., E.P., V.A., C.D.S., C.S., and R.R. are listed as inventors of full-length human monoclonal antibodies described in Italian patent applications no. 102020000015754 filed on June 30th 2020, 102020000018955 filed on August 3rd 2020, and 102020000029969 filed on 4th of December 2020, and the international patent system number PCT/IB2021/055755 filed on the 28th of June 2021. All patents were submitted by Fondazione Toscana Life Sciences, Siena, Italy. R.D.F. is a consultant for Moderna on activities not related to SARS-CoV-2. The remaining authors declare no competing interests.
Peer review information
Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Andreano, E., Paciello, I., Marchese, S. et al. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. Nat Commun 13, 3375 (2022). https://doi.org/10.1038/s41467-022-31115-8